What is Roth Capital’s Estimate for SPRY Q3 Earnings?

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) – Roth Capital issued their Q3 2025 earnings per share estimates for ARS Pharmaceuticals in a report issued on Tuesday, November 4th. Roth Capital analyst K. Bauser forecasts that the company will post earnings of ($0.44) per share for the quarter. Roth Capital currently has a “Buy” rating and a $30.00 price target on the stock. The consensus estimate for ARS Pharmaceuticals’ current full-year earnings is ($0.55) per share. Roth Capital also issued estimates for ARS Pharmaceuticals’ Q4 2025 earnings at ($0.45) EPS, FY2025 earnings at ($1.70) EPS, Q1 2026 earnings at ($0.46) EPS, Q2 2026 earnings at ($0.32) EPS, Q3 2026 earnings at ($0.05) EPS, Q4 2026 earnings at ($0.28) EPS, FY2026 earnings at ($1.11) EPS, FY2027 earnings at $0.08 EPS, FY2028 earnings at $1.30 EPS and FY2029 earnings at $2.24 EPS.

A number of other brokerages also recently commented on SPRY. Zacks Research downgraded ARS Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Wednesday, October 22nd. Wall Street Zen downgraded ARS Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, July 26th. Raymond James Financial set a $32.00 price objective on ARS Pharmaceuticals in a research report on Friday, September 26th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of ARS Pharmaceuticals in a research report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and two have given a Sell rating to the company’s stock. According to MarketBeat, ARS Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $31.80.

ARS Pharmaceuticals Stock Performance

NASDAQ SPRY opened at $9.05 on Thursday. ARS Pharmaceuticals has a fifty-two week low of $8.32 and a fifty-two week high of $18.90. The stock has a market cap of $894.41 million, a price-to-earnings ratio of -18.47 and a beta of 0.83. The business has a fifty day moving average of $10.12 and a 200-day moving average of $13.66. The company has a quick ratio of 5.98, a current ratio of 6.17 and a debt-to-equity ratio of 0.37.

ARS Pharmaceuticals (NASDAQ:SPRY) last posted its quarterly earnings results on Wednesday, August 13th. The company reported ($0.46) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.05). ARS Pharmaceuticals had a negative net margin of 42.74% and a negative return on equity of 21.85%. The business had revenue of $15.72 million during the quarter, compared to analysts’ expectations of $12.92 million.

Institutional Trading of ARS Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the company. CWM LLC raised its position in shares of ARS Pharmaceuticals by 243.7% during the 3rd quarter. CWM LLC now owns 2,547 shares of the company’s stock worth $26,000 after purchasing an additional 1,806 shares during the period. ANTIPODES PARTNERS Ltd acquired a new position in ARS Pharmaceuticals during the 1st quarter valued at approximately $37,000. PNC Financial Services Group Inc. boosted its position in ARS Pharmaceuticals by 78,100.0% during the 1st quarter. PNC Financial Services Group Inc. now owns 3,910 shares of the company’s stock valued at $49,000 after purchasing an additional 3,905 shares during the period. Osaic Holdings Inc. boosted its position in ARS Pharmaceuticals by 52.8% during the 2nd quarter. Osaic Holdings Inc. now owns 5,215 shares of the company’s stock valued at $91,000 after purchasing an additional 1,803 shares during the period. Finally, CX Institutional acquired a new position in ARS Pharmaceuticals during the 3rd quarter valued at approximately $92,000. Institutional investors and hedge funds own 68.16% of the company’s stock.

Insider Buying and Selling

In related news, insider Sarina Tanimoto sold 37,656 shares of the business’s stock in a transaction dated Wednesday, August 20th. The stock was sold at an average price of $14.09, for a total value of $530,573.04. Following the transaction, the insider owned 1,247,447 shares in the company, valued at approximately $17,576,528.23. The trade was a 2.93% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Richard E. Lowenthal sold 50,000 shares of the business’s stock in a transaction dated Thursday, August 21st. The stock was sold at an average price of $14.49, for a total value of $724,500.00. Following the completion of the transaction, the chief executive officer owned 1,196,494 shares in the company, valued at approximately $17,337,198.06. This trade represents a 4.01% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 112,500 shares of company stock worth $1,615,759. 33.50% of the stock is currently owned by corporate insiders.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.